Metformin glibenclamide tablets are oral hypoglycemic drugs and should be taken in individualized doses with close monitoring of blood glucose during administration. Specific usage should be under the direction of a physician. Metformin Glibenclamide Tablets is a combination of metformin and glibenclamide, and is indicated for patients with type 2 diabetes mellitus whose blood glucose remains unsatisfactorily controlled after dietary control alone and exercise therapy. The dose of Metformin Glibenclamide Tablets should be determined on an individual basis. For patients with type 2 diabetes mellitus whose blood glucose is no longer satisfactorily controlled with diet and exercise therapy, the recommended starting dose is 1 tablet (glibenclamide/metformin: 1.25 mg/250 mg) once daily with a meal. Blood glucose should be monitored closely during administration, and the dose may be increased every two weeks under the supervision of a physician until the lowest effective dose is reached. Adverse reactions are common hypoglycemic reactions, renal disease or renal insufficiency, hypersensitivity to metformin or glibenclamide, acute and chronic metabolic acidosis, type 1 diabetes mellitus and other patients are prohibited. Metformin glibenclamide tablets are prescription drugs, taking, dosage as well as reducing the dosage should be carried out under the guidance of a doctor, not blindly self-administered or adjusted.